Designing liposomal oral formulations aligned with physiology, payload properties, and scalable manufacturing

Liposomes have long been established as versatile and biocompatible carriers for biologically active molecules. Advances in manufacturing technology have dramatically broadened their application landscape, positioning them today as effective platforms for the oral delivery of pharmacologically active compounds, nutrients, and dietary supplements. Developing effective oral liposomal formulations, however, demands more than empirical optimization. It requires a strategy that simultaneously accounts for the complex physiological environment of the gastrointestinal (GI) tract, the physicochemical profile of the encapsulated payload, and the practical realities of scalable production. This work presents an integrative framework that unifies four critical decision-making axes: the Biopharmaceutics Classification System (BCS), Lipinski's Rule of Five, log P assessment and production process constraints. By mapping BCS categories onto specific GI absorption mechanisms, this framework enables the rational engineering of liposome architecture and properties to actively exploit physiological uptake routes. If the approach is effectively applied, liposomal carriers can achieve bioavailability enhancement that is to some degree independent of the payload's intrinsic membrane permeability and markedly less susceptible to food-effect interference compared to conventional oral formulations. Critically, aligning payload BCS class and log P with manufacturing feasibility supports the rational selection of production methods and excipient systems, striking a calibrated balance among encapsulation efficiency, release kinetics, physicochemical stability, and scale-up practicality. The power of this integrated approach is illustrated through two contrasting compounds, vitamin C (highly hydrophilic, BCS Class I) and vitamin D (highly hydrophobic, BCS Class IV), representing opposite ends of the physicochemical spectrum. These case studies demonstrate that tailoring liposome composition and processing conditions to the specific payload profile and GI physiological context can yield meaningful, nutritionally relevant gains in oral bioavailability for both hydrophilic and lipophilic molecules. This framework provides a scientifically rigorous and industrially actionable foundation for the rational development of next-generation oral liposomal formulations, systems that are not only mechanistically optimized but also commercially viable, ultimately contributing to improved therapeutic and nutritional health outcomes.